Trial Profile
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Dermatomyositis; Myositis; Polymyositis
- Focus Proof of concept; Therapeutic Use
- 06 Nov 2023 Results assessing efficacy and safety of RCI for treating refractory cutaneous DM published in the Rheumatology
- 11 Mar 2020 Results (N=8), 6 months follow up results, published in the Rheumatology
- 24 Oct 2018 Long Term Follow-up Results of myositis patients after 6 months of treatment (n=10) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting